Dynavax Technologies Co. (NASDAQ:DVAX) Receives Average Recommendation of “Buy” from Analysts

Shares of Dynavax Technologies Co. (NASDAQ:DVAX) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $12.50.

DVAX has been the subject of several analyst reports. Cowen reissued a “buy” rating on shares of Dynavax Technologies in a research note on Monday, June 3rd. William Blair reissued a “buy” rating on shares of Dynavax Technologies in a research note on Friday, August 16th. Royal Bank of Canada decreased their price objective on shares of Dynavax Technologies to $13.00 and set an “outperform” rating for the company in a research note on Friday, May 24th. BidaskClub raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday. Finally, Cantor Fitzgerald raised shares of Dynavax Technologies from a “neutral” rating to an “overweight” rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th.

In other news, SVP Robert Coffman sold 32,218 shares of Dynavax Technologies stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $4.58, for a total transaction of $147,558.44. Following the completion of the sale, the senior vice president now owns 132,470 shares of the company’s stock, valued at $606,712.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Francis Cano purchased 16,667 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were bought at an average cost of $3.00 per share, with a total value of $50,001.00. Following the purchase, the director now directly owns 118,484 shares of the company’s stock, valued at approximately $355,452. The disclosure for this purchase can be found here. Insiders own 4.90% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Ladenburg Thalmann Financial Services Inc. increased its holdings in Dynavax Technologies by 95.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 3,402 shares during the period. Bank of Montreal Can grew its holdings in Dynavax Technologies by 148.4% in the second quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 4,445 shares during the last quarter. Wedbush Securities Inc. purchased a new position in Dynavax Technologies in the second quarter worth $42,000. M&T Bank Corp grew its holdings in Dynavax Technologies by 29.5% in the second quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 3,116 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Dynavax Technologies in the second quarter worth $59,000. 82.41% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ DVAX opened at $4.32 on Tuesday. The company has a debt-to-equity ratio of 19.95, a current ratio of 4.30 and a quick ratio of 3.47. Dynavax Technologies has a 1 year low of $2.60 and a 1 year high of $14.35. The firm has a 50-day simple moving average of $3.51 and a two-hundred day simple moving average of $6.13.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.03). The firm had revenue of $8.30 million during the quarter, compared to the consensus estimate of $8.24 million. Dynavax Technologies had a negative return on equity of 304.71% and a negative net margin of 781.10%. The firm’s revenue for the quarter was up 564.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.63) EPS. On average, sell-side analysts expect that Dynavax Technologies will post -1.99 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Read More: How accurate is the Rule of 72?

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.